Wellbeing KGK Science Enters Phase II Clinical Trial Research Contract With Halucenex

Wellbeing’s KGK Science Enters Phase II Clinical Trial Research Contract With Halucenex

Evidence-based mental healthcare company Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA: SQ2) announced that its wholly-owned subsidiary KGK Science Inc. has entered into a research services agreement with Halucenex Life Sciences Inc., a psychedelic subsidiary of Creso Pharma (ASX: CPH) (OTC: COPHF) FRA: 1X8).

Wellbeing Digital Sciences focuses on the development and implementation of innovative clinical solutions utilizing psychedelic medicine and digital therapeutics supported by clinical research.

The new research agreement will see KGK conducting a planned Phase II clinical trial to test the efficacy of psilocybin on treatment resistant PTSD.

Details of KGK and Halucenex Research Contract

Under the research and services agreement with Halucenex, KGK will provide clinical trial protocol development, preparations for Phase II trials, data management and validation, statistical analysis and drafting of the final report (“Services”).

Najla Guthrie, CEO of Wellbeing and KGK, stated the organization’s were thrilled to be working with Halucenex for their planned phase II clinical trials to test the efficacy of psilocybin on treatment resistant Post Traumatic Stress Disorder (PTSD) noting the new partnership marks an important step in moving the industry that much closer to creating alternative medicines for a growing population base.

Guthrie was quoted as saying, “Over the past 25 years, we have successfully helped hundreds of companies with custom designed clinical trials and claim substantiation strategies that move products efficiently into the global markets.”

Bill Flemming, CEO and Founder of Halucenex, also commented on the agreement stating, “KGK is a leading contract research organization (CRO), offering high-quality clinical research trials and expert regulatory support for the nutraceutical, cannabinoid, hemp and psychedelic industries.”

Flemming said Halucenex was confident that KGK’s role will enable the organization to make considerable progress towards creating alternative treatment solutions to current pharmacological interventions.

About KGK Science

KGK is a major North American contract research organization based in London, Ontario that focuses on high-quality clinical trials and specializes in nutraceuticals and emerging health care products. The mission of KGK is to provide high-quality clinical trials for nutraceuticals and new health care treatments.

KGK is a firm that was formed in 1997 and is owned by Wellbeing Digital Sciences. The company has assisted hundreds of businesses with custom designed clinical trials and claim substantiation methods to enter into global markets.

In addition to providing consulting services, KGK provides expert regulatory support and compliance solutions through its other existing service lines such as participant recruitment, research support services, and consulting services.

Furthermore, KGK has published over 150 papers and conducted over 400 clinical trials across more than 40 indications with 25,000 participants in its database collecting over 10 million data points.

About Wellbeing Digital Sciences

Wellbeing Digital Sciences Inc. is a mental health firm that focuses on the development and implementation of cutting-edge clinical treatment options, such as psychedelic medicine and digital therapeutics, based on clinical research.

The mission of Wellbeing is bolstered by a network of North American clinics that provide forward-thinking therapies and other types of treatment, as well as a contract research organization that provides clinical trials services to clients seeking pharmaceutical development.

About Halucenex

Halucenex is a life-sciences startup that specializes in developing and licensing psychedelic chemicals for the pharmaceutical and nutraceutical markets, as well as conducting clinical trials on the medical benefits of psychedelic medicine.

Today, the business is engaged in psychedelic-assisted psychotherapy and medical research at a 6000 square foot medical facility in Windsor, Nova Scotia consisting of 6 treatment rooms and a secure laboratory.

Halucenex aims to have complete oversight of the product creation process, including mycological research, extraction technology, and synthetic formulation; as well as psychedelic-assisted psychotherapy and regulatory matters.

About Creso Pharma

Creso Pharma Limited (ASX:CPH) is a pharmaceutical company that creates the finest of cannabis to improve people’s and animals’ lives. It applies rigorous science and industry knowledge to the cannabis market in order to achieve the highest levels of quality.

The company develops cannabis and hemp-derived therapeutic, nutraceutical, and lifestyle products with a broad patient and consumer reach for human and animal health.

Creso Pharma strictly adheres to Good Manufacturing Practice (GMP) and production standards for its medicines as a marker of quality excellence.

The organization has worldwide rights to a number of innovative and proprietary delivery methods that improve the bioavailability and absorption of cannabinoids.

Leave a Reply

Your email address will not be published.

Previous Story

Journey Colab Announces Appointment of Joel A. Posener, MD as Chief Medical Officer

Next Story

Filament Health Join TheraPsil in World’s Largest Medical Psilocybin Access and Data Project